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A bstract
O rtiz, Thom as C., M.S. May, 1998 Pharm aceutical Sciences
Title; Synthetic Peptide Probes of the H um an  5-HT^^ R ecep tor/G  
P rotein  Interface
A dv iso r: Keith K. Parker, Ph.D.
^ c -r
To study  the interactions in G pro tein  /  receptor coupling, pep tide  
probes synthesized according to the published  sequences of the h u m an  5-HTj^ 
receptor w ere utilized in a m odel system  of h u m an  5-HTj^ receptors stably 
expressed in Chinese ham ster ovary (CHO) cells. A ctivity of these peptides 
w as determ ined  by their ability to displace a specifically-bound agonist, [^H]8- 
OH-DPAT, from  cells, as well as th ro u g h  signal transduction  assays 
m easu rin g  cAMP form ation. Previously, a 15 am ino acid pep tide (15mer) 
from  the transm em brane 5 /in trace llu la r loop 3 region (TM 5/i3) of th e  
hu m an  receptor has been show n to be biologically active in  these assays.
Two 15mers w ere synthesized to determ ine effects tha t n o n ­
conservative  am ino acid substitu tions have on the in teractions betw een  
receptor and  G protein. The first, altered at positions 6  and  7 from  its N - 
te rm in u s by substitu tion  of an arginine to glycine to G^^ )̂ at position  6 , 
and  pheny la lan ine  to alanine to A^^ )̂ at position  7, w hich  is te rm ed
ISm er GA. The second peptide included add itional substitu tions at positions 
8  to G^^ )̂ and 9 to A^^ )̂ from  the N -term inus, and is term ed 15m er 
GAGA. A th ird  synthetic peptide, term ed l lm e r ,  from  the T M 3/i2  reg ion  
contain ing  a highly conserved D/ERY m otif at the N -term inus, w as also 
characterized in the sam e m anner as the altered ISm ers.
Each of the synthetic peptide probes of the h u m a n  5-HT^^ receptors 
tested  produced  a concen tra tion -dependen t effect in  d isplacing th e  
specifically-bound agonist [^H]8 -OH-DPAT from  the receptors, w ith  IC50 
values in the low m icrom olar ranges The rank of potency w as l lm e r  > 
15m er GA > 15mer GAGA. This w as observed in all p reparations of th e  
receptor, includ ing  the w hole cell p reparations, indicating tha t each pep tide  
w as able to gain at least m oderate in tracellu lar access. In the signal 
transduction  assays only one of the peptides, ISm er GAGA, w as able to inhibit 
forskolin-stim ulated  cAMP production  g reater than  50% of the controls, w ith  
the l lm e r  from  the i2  site being the least active.
The findings support the cu rren t m odels of 7TM /GPCR, in th a t the N  
and  C -term ini of i2 and i3 are functional dom ains of receptor G p ro te in  
coupling, and  that the i3 site is im p o rtan t for effective receptor-G  p ro te in  
coupling  and  G pro tein  activation.
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Introduction
A. Serotonin Receptors
S ero ton in  (5-hydroxytryptam ine, 5-HT) is an  in d o lea lk y lam in e  
signaling  m olecule found  in n u m ero u s system s th ro u g h o u t the body, and  
thus is invo lved  in a num ber of physiological processes. H istorically, 5-HT 
w as know n initially  as bo th  sero tonin , due to vasoconstrictive effects d u rin g  
p latelet aggregation (1 ), and  en teram ine because of its actions on  the sm o o th  
m uscle in the in testinal m ucosa (2 ). 5-HT has been show n to be a 
n eu ro tran sm itte r  and n eu ro m o d u la to r in bo th  the central and  p e rip h e ra l 
nervous system s, as w ell as an autacoid (3).
D ysregulation of serotonergic system s has been im plicated in several 
pathophysio logical states. Serotonergic m echanism s are th o u g h t to be 
involved in hallucinations (4-5). There is m uch clinical evidence su p p o rtin g  
5-HT in v o lv em en t in m igraine headache (6-7), panic disorders (8 ), and  
depression  (3). Some experim ental evidence indicates tha t o ther d isorders 
such as T oure tte 's  syndrom e, sch izophren ia , autism , and m u ltip le  sclerosis 
are in som e p art due to serotonergic dysfunction (9).
Receptors tha t m ediate the actions of 5-HT w ere discovered in  the late 
1950's. Initially, tw o types of receptors for 5-HT w ere thought to exist (10) and  
w ere classified according to the ir pharm acological characteristics. Later 
stud ies using  radiolabled ligands found tw o distinct b ind ing  sties in the rat
fron tal cortex (11) called 5-HT^ , w hich displayed a h igh  affinity for pH] 5-HT 
and  5 -H T 2, w hich  h ad  a low affinity for [^H] 5-HT, b u t a h igh  affinity for pH] 
sp iperone. Soon thereafter, a th ird  class of 5-HT receptor w as characterized, 
the 5 -HT3 receptor (1 2 ).
U ntil recently, all receptors (5-HT or o therw ise) w ere identified  an d  
classified th ro u g h  purely  pharm acological m ethods. H ow ever, w ith  th e  
ad v en t of m olecular biological techniques, the num ber of receptors and  
subtypes w ith in  a fam ily has grow n substantially. A t present, the fam ily of 
receptors for 5-HT can be d iv ided into seven types, and  fu rther su b d iv id ed  
into several sub types (13-14). These relationships are sum m arized  in table 1.
Table 1: Current C lassification of Receptors for Serotonin. A dapted from Hoyer, et al,  1994 
(13) and Kennett, 1997(14).
Receptor: 5-HTi 5 -H T 2 5 -HT 3 5 -H T 4 5 -H T 5 5-H T, 5 -H T 7
G protein  
Linkage: Gi/o ^q / 1 1 Gs Gs Gs Gs
Effector
System : AC
(-)
PLC
(+)
N a V K V
Ca++
Ion
channel
AC
(+)
AC
(-) /
??*
AC
(+)
AC
(+)
Subtypes: A ,B ,D ,
E,F
A,B,C A ,B*
AC = adenylyl cyclase, PLC = Phospholipase C. For a description of G proteins, see table 2. 
*The G protein /signal transduction for S-HT^p has yet to be elucidated.______________________
These receptors have been classified according to a n u m b er of criteria; 
pharm acological, cD N A -deduced p rim ary  am ino acid sequences, signal 
tran sd u c tio n  and effector m olecules (13,15-16). 5-HTg receptors are the lo n e  
ligand-gated  ion channel receptor in the 5-HT family, closely related  to o th e r
ion channel receptors (GABA, glycine, A M P A /k ain a te  g lutam atergic and  
nicotinic cholinergic) in tha t they consist of a large glycosylated ex tracellu lar 
N -term inus, w ith  four subsequen t transm em brane segm ents (17).
The rem ainder of the know n 5-HT receptors are m em bers of a larger 
superfam ily  of seven transm em brane receptors (7TMR) w hich  are linked v ia  
h e tero trim eric  guanine nucleotide b ind ing  pro teins (G proteins) to th e ir  
effector m olecules (18). As prev iously  m en tioned  in table 1, receptors of th e  
5-HT^ type are generally associated w ith  Ĝ . Receptors of the S-HT^ type are 
coupled  w ith  G^, resulting  in phospho inositide  tu rn o v er and in trace llu la r 
Ca^^ m obilization  th rough  the phospho lipase  C pathw ay. The o thers, 
a lthough  less well characterized, appear to be coupled to Gg, w ith  increases in  
cellu lar cAMP.
B. 5-HTj^ Receptors
The 5-HT^ receptors w ere originally g rouped  together because of h ig h  
affinity for 5-HT and 5-carboxyam idotrypfam ine (5-CT), as w ell as being 
an tagonized  by agents like m ethysergide, bu t are now  grouped  m ain ly  o n  
m olecular biological criteria (13). All 5-HT^ m am m alian  subtypes are encoded 
by a single in tronless gene sharing  greater than  60% identity  across th e  
p u ta tiv e  transm em brane dom ains (13). All know n subtypes of the 5-HT^ 
receptor class have been cloned and are negatively coupled to adenylyl cyclase 
(AC) th rough  Ĝ  (13).
The 5-HT^^ receptors are am ong the m ost well stud ied  subtype of th is 
class of receptor. receptors are p rim arily  neuronal, are found  m a in ly
in the  central nerv o u s system  (CNS) w ith  som e exam ples located 
peripherally . In the CNS, h igh  receptor densities lie w ith in  the dorsal raphe, 
h ippocam pus, and  th ro u g h o u t the cortex (19). 5-HT^^ receptors are believed  
to p lay  roles in body tem pera tu re  regulation , feeding and sexual b eh av io r, 
anxiety, depression , and  m igraine headache (19). The receptor has been  
cloned from  a n u m b er of species, includ ing  the rat and h um an , w hich  share  
99% identity  in  the transm em brane regions (20-21). The h u m an  5-HT^^
receptor w as discovered in a cDNA library using  a (3-adrenergic receptor probe 
(20) and the clone, term ed G-21, w as subsequently  found to contain the 5-HT^^ 
receptor (2 2 ).
In m ost expression system s, the receptor is negatively  coupled to AC 
via Gj (23). H ow ever som e expression system s display both  inh ib ition  of AC 
and activation  of the phospho lipase C (PLC) pathw ay, a lth o u g h  PLC 
activation  is no t as efficient as the receptor-m ediated  inh ib ition  of AC. T he 
reason  for th is is not clear, since this p h en o m en o n  has no t been detected in  
tissue p repara tions (23) and  thus has no know n physiological relevance.
C. Seven transmembrane/G protein-coupled receptors (7TM/GPCR)
7TM /G PCR  are a superfam ily of integral m em brane pro teins tha t relay 
in fo rm ation  across cellular m em branes, respond ing  to such  d iverse
extracellu lar stim uli as photons, pherom ones, odorants, peptides, and  
m o n o am in es (18,24). These serpen tine  m em brane pro teins possess a 
m u ltip ly  glycosylated extracellular am ino te rm in u s and in tracellu lar carboxy 
tail of vary ing  length. There are 7 pu ta tive  transm em brane  (TM) d o m ain s
fo rm ing  a-helices, arranged  in a d isto rted  cylinder-like fashion (25), the
ex tracellu lar core of this cylinder form ing the hypothesized  ligand-b ind ing  
d o m ain .
In terspersed  betw een  the TM dom ains on  the cytoplasm ic face are three 
in tracellu lar (il-3) loops (som e receptors m ay exhibit a fou rth  in trace llu la r 
loop by v irtu e  of a palm itoy lated  residue on  the carboxy te rm inus, w h ich  
inserts itself into the m em brane (26)). These in tracellu lar loops form  the  
contact site for the hetero trim eric  G pro tein . A schem atic of a generic 
7TM /G PCR  is p resented  in figure 1.
N term
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Figure 1: Schem atic of a typ ical seven transmembrane/G protein
coupled receptor. N  = sties of N -linked  glycosylation, C = sites of 
cysteine m odification, e l-3  = extracellular loops, i l -4 = in tracellu lar  
loops, TM l-7 transmembrane dom ains. From Spiegel, 1995 (26).
Initially, this tertiary  structure w as deduced  from  hydrophobicity  plots 
of p rim ary  am ino acid sequence. U ntil recently, the basic characteristics and  
structu re  of these receptors have been im plied  from  bacteriorhodopsin , a 7 
transm em brane protein . A lthough it is no t G protein-coupled , and  shares n o  
sequence hom ology w ith  7TM /GPCR, the bacterio rhodopsin  m o d e l 
nonetheless has p ro v en  to be useful in m any respects (25). N ow , a low - 
reso lu tion  crystal structu re  of rhod o p sin  has been elucidated  (27-28), 
p rov id ing  a true G protein-coupled  receptor for m odelling purposes.
U pon agonist b inding , a series of conform ational changes take place in  
the TM dom ains, of w hich  m ovem en t of TM6  causes a shift in  TM3. T h is 
alters the cytoplasm ic face of the i3 loop region (betw een TM5 and TM 6 ), th u s  
changing receptor affinity for the G pro tein , w hich in tu rn  is activated. Site- 
d irected m utagenesis (29), and receptor chim eras have dem onstra ted  tha t i2, 
i3, and  the carboxy te rm in u s/i4  are sites for re c e p to r /G protein  coupling (30).
D. Heterotrimeric G Proteins
H eterotrim eric G pro teins are a fam ily of m em brane-associated  signal 
transducers that couple 7TMRs to their effector m olecules (31). C on tain ing  a ,
p, an d  Y subunits, they are classified according to the function of the a  su b u n it
(32-33). The a  subunits can be d iv ided  into roughly  4 classes, based  u p o n  their
am ino acid sequences and  function (33). These relationships are su m m a rize d  
in table 2 .
Table 2: Fam ily of oc Subunits of Heterotrimeric G Proteins in M ammals. From Conklin and 
Bourne, 1993 (33).
C lass A lpha Subunit Effectors Intracellular
Message
Location
s «S (+) AC, open Ca"“̂ channels (+) cAMP, (-) MP Ubiquitous
«olf (+) AC (+) cAMP O lfactory
ep ith e liu m
i / o / t (Xi, (X;, (X3 (-) AC, open channels (-) cAMP, (+) MP Ubiquitous
« 0 close Ca^  ̂ channels (-) MP Brain
(') AC (-) cAMP Brain
(+) cGMP-PDE (-) cGMP Rods
CXj2 (+) cGMP-PDE (-) cGMP Cones
®̂gust Unknown Unknown Taste buds
q Otl4/ ^̂ 15 (+) PI-PLC, P subtypes (+) IP3 , DAG Ubiquitous
12/13 Unknown Unknown Ubiquitous
AC = adenylyl cyclase, DAG = diacylglycerol, cGMP-PDE = cyclic GMP phosphodiesterase, IP3  
= inositol (fris)phosphate, MP = membrane potential, PLC = phospholipase C, PI = 
p h o sp h a tid y lin o sito l._________________________________________________________________________
In its inactive state, the trim er has GDP tightly b o u n d  to th e
guan ine nucleotide b ind ing  site/G T Pase site on the a  subunit. In this state,
G„ has a very  h igh  affinity for Gp  ̂and the receptor. U pon activation of the G
pro tein , the a  subun it disassociates from  the receptor and the (3y d im er 
because of a conform ational change due  to the exchange of bound  GDP for 
GTP on the a  subunit. The G„-GTP subun it then  activates an appropria te  
effector m olecule and u p o n  GTP hydrolysis this regulation is te rm in a te d -th u s  
leaving  GDP bound  to G„. The now  inactive G„ re-associates w ith  Gp.̂  and is 
ready  to begin  the cycle again. This G protein  cycle is p resented  in figure 2.
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O nce activated, G proteins can be p rev en ted  from  cycling in the
presence of a nonhydrolyzable substrate such  as GTP7S, or A IF / w hich is
p resum ed  to resem ble the transition state of GTP. This can also be caused by
bacterial endotoxins such as
GDP GTP
R*( aJPY
Figure 2: The G protein-GTPase cycle.
a , P, Y = G protein subunits, R* = 
receptor, agonist-bound h igh  a f f in ity  
state, E* = activated effector m olecule, 
E = inactive effector m olecule. Pi = 
inorganic phosphate. From Bourne and 
Conklin, 1993 (33).
pertussis or cholera toxins (31),
w h ich  A DP-ribosylate the a
subun it, changing the active site 
an d  p rev en tin g  hydrolysis of 
GTP. In e ither case, the G 
p ro te in  is unable  to hydro lyze 
its GTP or hom ologue substrate, 
and  its actions at any effector 
m olecule are essen tially  
irreversib le . Once it was
believed that only G„ was
invo lved in in trace llu la r
signaling  and effector
regulation . H ow ever, recent
evidence reveals a role for the Gp  ̂ d im er in both the ac tiva tion  an d
regu la tion  of in tracellu lar effector m olecules once disassociated from  Ĝ  ̂(33).
Some roles ascribed to Gp  ̂ regulation  are m odu la tion  of and  Ca^^ io n  
channel function, control of several p ro te in s in the m itogen  ac tiva ting
p ro te in  (MAP) kinase cascade, adenylyl cyclase, phospholipase Ag, and the  
p lasm a m em brane Ca"̂  ̂ pum p (34-35).
It is interesting to note that w hen  coupled to the receptor, the G p ro te in  
influences the affinity of the receptor w ith  respect to agonist b ind ing  (11,36).
W hen inactive Ĝ ^̂ -GDPp̂  is coupled to the receptor, the receptor displays a
h igh  affinity for agonist b inding. As the agonist binds, the receptor shifts
from  h igh  to low affinity, once GTP is exchanged for GDP on G a.
E. Summary
The scope of this thesis is necessarily lim ited to w hat perta ins to the  
b iochem istry  of h u m an  5-HT^,^ receptor. H ow ever, as a m em ber of th e  
7TM /G PCR superfam ily , a tho rough  u n d erstan d in g  of all the co m p o n en ts  
invo lved  is necessary to grasp the hypothesis and the m ethodology  used in  
testing it. Figure 3 displays a schem atic of an  expressed 5-HT^^ recep to r/G 
protein-effector system  to detail the com plex rela tionsh ips invo lved  in these 
system s.
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Figure 3: 5-HT^a receptors, effectors, and second messengers of heterologous expression system s. 
A A = arachidonic acid, AC = adenylyl cyclase, DAG -  diacylglycerol, IP3  = inositol 
(fris)phosphate, PLA, = phospholipase Ai, PLC = phospholipase C, PIP2  = 
p hosphatidylinosito l (Ws)phosphate, PKC = protein kinase C. From Raymond (19).
H ypothesis and Specific Aims
A. Hypothesis
The p rim ary  purpose in this investiga tion  is to gain a better 
u n d ers tan d in g  of the functional dom ains lying at the interface betw een G 
p ro te ins and  the h u m an  5-HT^^ receptor. C urrently , several m ethods are 
em ployed  to investigate the interaction betw een the cytoplasm ic in trace llu la r 
loops of the receptor (il-i4/carboxyl term inus) and the G p ro te in  in  
7TM /G PCR. A m ong these are construction of receptor chim eras, site-directed 
m utagenesis of am ino acid residues, deletion of functional dom ains, and  
pep tide  probes from  both  natu ral and synthetic sources.
It is hypothesized  tha t synthetic pep tide  probes designed to m im ic th e  
in tracellu lar loops of the h u m an  5-HT^^ receptor w ill com pete w ith  th e  
receptor for b ind ing  to the G protein. It is fu rther hypothesized  tha t these 
peptides w ill alter the function of the receptor in a m an n er th a t can be 
quantifiable. Results from  experim ents u tilizing  these pep tides w ill be 
in terpretab le in such a way as to p rov ide  useful in fo rm ation  on th e  
m olecular determ inan ts and functional dom ains th a t com prise the h u m an  5- 
recep to r/G  protein  interface, and  thus can be u tilized to study  receptor-G  
p ro te in  coupling.
This approach has been used in a num b er of 7TM /G PC R system s, 
includ ing  various horm one receptors (37), opioid  (38), and  m ost relevan t
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here; the 5-HT system  (39). Previously, our laboratory  has established tha t a 
15 am ino acid pep tide  (15mer) from  the transm em brane 5 /in trace llu la r loop 3 
region  (TM 5/i3) of the h u m an  5-HT^^ receptor is biologically active w ith  
respect to agonist inh ib ition  and signal transduction  (40). Two m odified  
15mers have been synthesized to determ ine effects tha t n o n -co n se rv a tiv e  
am ino acid substitu tions have on the in teractions betw een receptor and  G 
pro tein . The sites of a lteration  for 15mer w ere selected by in te rp re ta tion  of 
experim ental observations from  other groups w orking w ith  7TM /G PCR (41). 
The first alterations to the 15mer is at positions 6  (R^^  ̂ to Ĝ ^ )̂ and 7 (F̂ ^̂  to 
A^^^) from  its N -term inus. This new  pep tide  is term ed 15mer GA. T he 
second, term ed 15mer GAGA, includes fu rther substitu tions to the 15mer GA 
at positions 8  (R̂ ^̂  to Ĝ '̂̂ ) and 9 (P^  ̂ to A^^ )̂ from  the N -term inus.
A th ird  peptide, an l lm e r , w ill be tested in the sam e parad igm  to 
determ ine  if sim ilar in teractions betw een the receptor and G pro tein  occur 
and  can be observed using  sim ilar techniques at a site distinct (the TM 3/i2 
region) from  the 15mers. This region w as selected as it contains a h igh ly  
conserved m otif near its N -term inus. M ost 7TM /G PCR contain a D/ERY 
m otif near the T M 3/i2  junction , and as such it has also been im plicated as a 
functional dom ain .
These pep tide  probes have been synthesized according to the pub lished  
h u m an  5-HT^^ receptor sequences (20). Figure 4 displays the sequences and  
dom ains of the receptor tha t the pep tides are p resum ed  to mimic.
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15mer: IFRAARFRIRKTVKK
llm er: lALDRYW AITD
ISm erGA: IFRAAGARIRKTVKK 
ISmer GAGA: IFRAAGAGARKTVKK
Figure 4: Schem atic of human S-HT^a receptor and peptides used to probe the receptor/G  
protein  interface. Alterations to the original ISmer are underlined. Conserved D/ERY m otif in  
l lm e r  in boldface. Figure adapted from Katzung (42). Sequences from KobÜka, et al (20).
The size requ irem en t of these peptides uses p rev ious w ork  w ith  
receptom im etic pep tides of various 7TM /G PCR as a guideline. M ost of these 
stud ies utilize peptides in the range of ten to tw enty  am ino acids, b u t fu rth e r  
w ork  in th is area is needed  to u n d erstan d  the size and  s tru c tu ra l 
requirem ents. The structu re  of these peptides has only been  estim ated  by 
com paring  structures from  sim ilar pep tide probes and th ro u g h  energy 
m in im iza tio n  during  m olecular m odelling. T hree-d im ensional energy 
m inim ized structures of the pep tides are p resen ted  in appendix  3.
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B. Specific aims
To prov ide the data necessary to evaluate the hypothesis sta ted  on page 
1 1 , the specific aims are to:
1 . Characterize the actions of the 15mer G A w ith  the G p ro te in  by 
m easuring  agonist inh ib ition  in w hole cells, as well as in m em brane and  
solubilized p reparations of the receptor. C haracterization  w ill also en ta il 
m easuring  cAMP form ation, thus d eterm in ing  if G pro tein  /  receptor 
interaction is uncoupled, or if GA can activate the G pro tein  directly.
2. Test the ability of ISm er GAGA to interfere w ith  the re c e p to r /G protein  
interface. Again, agonist inh ib ition  in w hole cells, m em brane, and  
solubilized preparations of the receptor w ill be m easured . cAMP fo rm a tio n  
w ill also be m easured  to determ ine if ISm er GAGA uncouples the receptor 
from  signal transduction .
3. D eterm ine if the l lm e r  is biologically active in agonist in h ib itio n  
assays. If so, this w ill indicate a possible site of the G p ro tein -recep to r 
in teraction. If the l lm e r  is determ ined  to be active, fu rther characterization  
w ill entail m easuring  cAMP form ation.
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Bioactivity of these peptides are assessed by their ability to displace a 
specifically-bound agonist, as w ell as effects on the form ation  of second 
m essengers th rough  signal transduction  assays. The agonist inh ib ition  assays 
w ill be based u p o n  the w ell-know n alterations observed in agonist b ind ing
u p o n  ad d itio n  of GTP or stable analogues like GTP7S (11,36). As GTP (or
analogue) b inds to the agonist-receptor-G  p ro tein  com plex, it disassociates th e  
com plex. This disassociation shifts the affinity state of the receptor from  a 
h igh  (coupled w ith  G pro tein /G D P) to a low  affinity state, w ith  respect to 
agonist b inding. This is occurs in a concen tra tion-dependen t m anner. T hus, 
if these pep tide  probes do in fact com pete for b ind ing  sites on the G p ro te in  
w ith  receptor-agonist com plex, a concen tra tion -dependen t d isp lacem ent of 
the specifically bound  agonist w ill be observed. This w ill p rov ide ev idence 
tha t pep tides com pete w ith  the receptor for the G pro tein  and  effectively 
uncouple  it from  the receptor. This w ill no t only be tested in w hole cells 
expressing the receptor and  crude m em brane p reparations of these cells, bu t 
also in solubilized receptors, to exam ine the effects of lipid m em branes on th e  
peptides' activities. Since all barriers to the peptides gaining in trace llu la r 
access have been  rem oved and high-affinity  G protein-receptor coupling has 
been observed in  solubilized receptor p repara tions (43), one w ould  expect an  
increase of peptide-G  pro tein  in teraction  if lip id  m em branes pose a barrier to 
these peptides.
If the peptides in teract w ith  the G pro tein , as de term ined  by agonist 
inh ib ition , th en  there shou ld  also be m odu la to ry  effects by the pep tides o n
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even ts dow nstream  from  the receptor. This w ill be tested th ro u g h  
exam ina tion  of the peptides' effects on second m essenger form ation. T he
h u m a n  5-HTj^ receptor m ost effectively couples w ith  specifically
w h en  expressed in CHO cell cultures (44). In a m odel system  treated w ith  
forskolin , an  activator of adenylyl cyclase, trea tm en t w ith  an agonist sh o u ld  
cause a decrease in the second m essenger cAMP th rough  receptor ac tiva tion  
and  subsequen t G^-mediated inhibition of adenylyl cyclase. H ow ever, if the G 
p ro te in  is uncoup led  from  the receptor by one of the peptide probes, th e re  
shou ld  be no decrease in cAMP production  in the presence of a 5-HT^^ 
agonist, as Ĝ  is not able to interact w ith  agonist-activated receptor. H ow ever, 
there is a possibility that a receptom im etic pep tide could re ta in  en o u g h  
structu ra l characteristics of the agonist-bound receptor. If this w ere th e  
scenario, then  the pep tide m ight also be able to inhib it cAMP form ation  in  
our parad igm , by direct activation of Ĝ .
M aterials and M ethods
A. Chemicals
Chem icals w ere obtained from  the follow ing sources: H am 's F-12
m ed ium , Dulbecco's M odified Eagle m ed iu m  (DMEM), Earle's Balanced Salt 
so lu tion  (EBBS), trypsin, and Geneticin® (GIBCO/BRL; G aithersburg, MD). 
Fetal calf serum  (FCS) and Calf serum  (CS) (Sum m it Biotechnology; Fort 
Collins, CO). T ris(hydroxym ethy l)am inom ethane (Tris base), N-[2- 
H ydroxyethyl]p iperazine-N '-[2-ethanesulfonic acid]) (HEPES), d iso d iu m  
ethy lam nie(d iam ine) tetraaceetic acid (EDTA), and  calcium  chloride (Baker 
Chem ical Co.; Phillipsburg, PA). M ianserin , pargyline, d ith io th re ito l (DTT), 
3 -isobu ty l-l-m ethy l-xan th ine  (IBMX), sod ium  cholate, ap ro ton in , and  
soybean trypsin  inhibitor (Sigma Chem ical Co.; St. Louis, MO). [^H]ketanserin 
and  [^H]8 -hydroxy-2 -(d i-N -propylam ino)tetralin  (pH]8 -OH-DPAT) (N ew  
E ngland N uclear; Boston, MA). D iethyl ether (Fisher Scientific; Pittsburg, 
PA). D im ethysulfoxide (DMSO) (M allinckrot-Baker; Paris, KY). L eupeptin , 
benzam id ine, and  G 418 sulfate (Calbiochem ; Lajolla, CA). Forskolin  (ICN; 
Costa M esa, CA). Biotrak® [^^I]cAMP rad io im m unoassay  (RIA) k it 
(A m ersham  Lifesciences; A rlington R igh ts, IL). Enzym e im m unoassay  (EIA) 
kit for cAMP w as obtained from  either C aym an Chem ical (A nn A rbor, MI) o r 
A ssay D esigns (Ann A rbor, MI). Serotonin w as obtained  from  either ICN or
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Calbiochem . O ther chem icals and  reagents w ere obtained from  ad d itio n a l 
com m ercial suppliers.
B. Cell Culture
CHO cells expressing the h u m an  5-HT^^ receptor w ere cu ltu red  in
m onolayer using  H am 's F-12 m edium  fortified w ith  10% FCS and  200 |ig /m L
Geneticin® (G 418 sulfate). C ultures w ere m aintained at 37° C in a h u m id ifie d  
atm osphere of 5% CO 2/ 95% air. U pon confluency (5-7 days), cells w ere e ith e r  
used  in assays or subcultured.
C. Agonist Inhibition Assays
W hen confluent, cells from  either 80 cm^ or 175 cm^ flasks w ere 
harvested  w ith  0.25% trypsin  in physiological saline w ith  subsequent low - 
speed centrifugation in ice-cold m edia. The resulting  pellet w as resuspended  
in ice-cold EBBS, follow ed by centrifugation. Collected cells received one of 
the follow ing treatm ents, according to p reparation  of receptor desired:
(1) W hole cell p rep ara tio n s: The collected cells w ere suspended  in 30 
vo lum es of ice-cold b ind ing  buffer (50 m M  Tris, 4 mM , CaClj, 10 |iM  
pargyline, p H  7.4). This suspension w as used directly in  the assay.
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(2) M em brane p rep ara tio n s: To obtain  crude m em brane p rep ara tio n s 
of the receptor, the collected cells w ere suspended  in  ice-cold b ind ing  buffer 
w ith  subsequent centrifugation at 40,000 x g  for 45 m inu tes at 4° C to lyse th e  
cells. This crude m em brane fraction w as then  re-suspended  in 30 mL ice-cold 
b ind ing  buffer and subjected to hom ogen ization , first on glass, then  w ith  a 
B rinkm ann Polytron.
(3) Solubilized receptor p rep a ra tio n s: Collected cells w ere placed in 1 
mL of solubilizing buffer (20 m M  Tris, 0.6% sod ium  cholate, 1 m M  EDTA, 1
m M  DTT, 100 m M  NaCl, 1 mM  benzam idine, 10 |ig /m L  leupep tin , 100
m g /m L  soybean trypsin  inhibitor, and 10 p g /m L  apro tin in , pH  8.0) on ice for
1 hour. A fter centrifugation at 40,000 x g for 40 m inu tes at 4° C, th e  
su p ern a tan t w as rem oved and d ilu ted  to 30 mL in ice-cold b ind ing  buffer to 
be used  in the assay.
All p reparations w ere kept on ice th ro u g h o u t the assay. P ro te in  
conten t w as determ ined  using the Bradford m ethod  (45). D isplacem ent of 
pH ]8 -OH-DPAT (specific activity of 132.8 C i/m m o l) from  the receptors w as 
d eterm ined  using  m odifications of w ell-established protocols (46-48). Assays 
w ere ru n  in triplicate, incubated in a sh a k e r/b a th  at 30° C for 30 m in. Each 
reaction  m ix ture consisted of 700 pi receptor p repara tion , 100 pL of e ith e r
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b ind ing  buffer or 10  fiM serotonin in b ind ing  buffer to determ ine non-specific
binding, 100 )llL 0.50 nM  pH ]8 -OH-DPAT and  100 |iL of peptide, y ielding a total
volum e of 1 mL. Incubations w ere stopped  w ith  4 mL of ice-cold 50 m M  Tris 
buffer and rapid  filtration over W hatm an  G F/B  or, in the case of so lubilized 
receptor preparations, W hatm an  G F/F  glass fiber filters. This is follow ed 
w ith  tw o subsequent 5 mL w ashes, for a total w ash  vo lum e of 14 mL. Filters 
w ere counted in 5 mL of Ecoscint® liquid scin tillation  fluid in a Beckm an LS 
6500 liquid  scintillation counting  system .
D. cAM P Determination
To determ ine cAMP form ation, an  intact cell cu lture m ethod  w as used  
(46,49). W hen confluent, the m edia from  CHO cells grow n either in 12 or 24 
w ell plates w as rem oved. A fter two w ashes w ith  serum -free m edia, cells
w ere treated in 0.5 mL serum -free m edia w ith  100 |iM  IBMX w ith  the final 
concentrations of 30 juiM forskolin, 10 |liM  serotonin, and  either 114 |llM  (15mer 
G A), 124 gM  (ISm er GAGA), or 131 pM  ( llm e r)  of pep tide and then incubated
for 20 m inu tes at 37° C, w ith  agitation after 10 m in. W ells w ere th e n  
aspirated and 0.5 mL of 100 mM  HCl w as added, and  the plate w as incubated 
for 10  m inu tes, w h ereu p o n  well contents w ere rem oved and centrifuged at 
4000 rpm  for 15 m inutes at 4° C. Supernatan ts w ere extracted four tim es w ith  
H jO -saturated diethyl ether. The aqueous extracts w ere desiccated o v e rn ig h t
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at 60° C. cAMP w as quantified  w ith  a RIA kit using  gam m a counting , or a n  
EIA kit using  a plate reader at X. = 405 nm .
E. Peptide Synthesis and Preparation
Peptides w ere synthesized utilizing  solid-phase synthesis on an  ABI 
431A au tom ated  pep tide  synthesizer, using am ino acids from ABI. Fo llow ing  
synthesis, pep tides w ere purified  w ith  a W aters 625 HPLC System  u sin g  
acetonitrile and  aqueous 2 mM  HCl gradients, and lyophilyzed. Peptides w ere 
in itially  d issolved in deionized w ater, or in the case of l lm e r , 5% DMSO in  
deion ized  w ater. A t h ighest concentration of l lm e r  run , the final 
concen tration  of DMSO w as 0.5%. C ontrol experim ents show ed th a t 
concentrations of 0.5% DMSO had  no effect on our system. S ubsequent 
d ilu tions of the peptides w ere in b ind ing  buffer, or m edia w hen  used  in th e  
cAMP assays.
F. Data Treatment
G raphing  and non-linear regression, as w ell as statistical analysis w as 
w ith  com puterized  procedures (CA Cricket G raph III®, P rism  G raph  Pad®, 
M icrosoft Excel®, StatView 512+®).
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(1) A gonist inh ib ition  assays: Results are expressed as percent of
controls. IC50 values w ere determ ined from  non-linear regression analysis of 
dose-response curves. A pparen t values w ere determ ined  from  ICgo’s 
according to the Cheng-Prusoff relationship  (50);
IC50
Ki = ----------------
1 + [L ]/K d
W here [L] is the concentration  of the rad io ligand  and is its respective 
equ ilib rium  disassociation constant.
(2) cAMP assays: S tandard curves w ere prepared  and subjected to
linear regression analysis. From  the standard  curve, u n k n o w n  quantities of 
cAMP could be calculated. Data expressed as percent of fo rsk o lin -s tim u ated  
contro ls.
R esu lts
A. 15mer G A  Peptide
15mer G A, the first of the altered 15mer peptides to be characterized, 
p roduced  concen tra tion -dependen t effects as determ ined  to inh ib ition  of 
[^H]8 -OH-DPAT b ind ing  in w hole cell (figure 5), m em brane (figure 6 ), and  
solubilized (figure 7) p reparations of the receptor. IC50 and Kj values ob tained  
for the ISm er GA w ere sim ilar in each receptor p repara tion  (table 3), w ith  an
overall IC50 value of 59.7 ± 6.09 [iM, and resu lting  apparen t of 32.5 ± 3.33 
pM .
Table 3: IC5 0  and K; Values for ISmer GA. Values expressed in pM
Receptor Preparation IC 5 0 Ki
W hole cell 58 31.6
Membrane 69 37.6
S olu b ilized 52 28.4
Average ± SEM 59.7 ± 6.09 32.5 ± 3.33
In second m essenger assays, the 15mer GA w as able to produce a 
m odest, b u t significant (p<0.01) decrease in  cAMP form ation, w hen  com pared  
to the forskolin  controls. This decrease w as no t significantly different th a n  
the 5-HT trea tm en t alone or w hen  5-HT w as com bined w ith  the pep tide, as 
show n in figure 8 . This suggests that in add ition  to the 15mer GA com peting  
w ith  the receptor for the G protein , it apparen tly  can assum e the
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con fo rm ation  of the agonist-activated receptor. This w ould  then  activate 
subsequently  inhib iting  forskolin -stim ulated  cAMP production  in a s im ila r  
m anner as an  agonist activated receptor.
The region of i3 from  w hich  the orig inal ISm er w as based u p o n  is 
h igh ly  conserved across several species, and the original ISm er w as show n to 
be active in  rabbit cortex m em branes (40). Therefore, a brief investiga tion  w as 
conducted  to determ ine if the ISm er G A could display cross-species activity by 
u tilizing  m em brane p reparations of ra t cortex. The rat S-HT^^ receptor differs 
from  the h u m an  receptor only by one am ino acid in  the region of the IS m er 
GA. In position  tw o from  the C -term inus there is a substitu tion  for lysine 
w ith  arg in ine (21) in the rat receptor. This substitu tion  is no t con ta ined  
w ith in  the region altered in the ISm er GA. Figure 9 show s the resu lts of th is  
experim ent, w ith  sim ilar levels of d isplacem ent of bound  agonist observed.
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Figure 5: Inhibition  of [^H]8 -OH -DPAT binding by ISmer GA in w h o le  cells expressing th e  
hum an S-HTi^ receptor. Results are expressed as the mean ±  SEM of at least 3 experim ents run 
in triplicate. Conditions are as described in the Materials and Methods section.
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Figure 6 : Agonist inh ib ition  by ISmer GA in membrane preparations of the human S-HT^a 
receptor. Results are expressed as the mean ± SEM of at least 3 experiments run in tr ip lica te . 
For experim ental conditions refer to the Materials and Methods section.
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Figure 7; Inhibition  of [^H]8 -OH-DPAT binding by ISmer GA in so lu b ilized  human S-HT^a 
receptors. Results are expressed as the mean ± SEM of at least 3 experiments run in tr ip lica te . 
C onditions are as described in the Materials and Methods section.
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Figure 9: A bility  o f ISmer GA to inhibit pH ]8 -O H -DPA T binding in membrane preparations of 
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receptor are show n for comparison. Results are expressed as the mean ± SEM of 2 experim ents 
run in triplicate. C onditions are as described in the Materials and Methods section.
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B. ISmer GAGA Peptide
The second of the altered 15mer pep tides based upon  the 13 region of 
the h u m a n  receptor, ISm er GAGA, also gave a concen tra tion -
d ep en d en t effect in the agonist inh ib ition  assays. D isplacem ent of pH]8-OH- 
DPAT from  w hole cell (figure 10), m em brane (figure 11), and so lub ilized  
(figure 1 2 ) p reparations of the receptor revealed a low er potency th an  that of 
the ISm er GA, w ith  resu ltan t h igher IC5Q and  values (table 4). A n o v era ll
IC50 value of 103.7 ± 8.04 |iM , and resulting apparen t Kj of S6.5 ± 9.39 |iM  w ere
calculated. These values are about tw ice those of ISm er GA.
Receptor Preparation ICgo Ki
W hole ceil 107 58.4
Membrane 113 61.6
S o lu b ilized 91.0 49.5
Average ± SEM 103.7 ± 8.04 56.5 ±  9.39
W hen assayed for effects on second m essenger p roduction , IS m er 
GAGA strongly inhib ited  forskolin -stim ulated  cAMP production , and th is  
resu lt w as highly  significant (p<0.001), a lthough  w hen  com bined w ith  S-HT, 
the resu ltan t inh ib ition  is no m ore than  S-HT alone, as show n in figure 13. 
This is different than  w ith  the ISm er GA, as there seem s to be no effect of th e  
pep tide  on S-HT-m ediated inh ib ition  of fo rsko lin -stim ulated  cAMP 
fo rm atio n .
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Figure 10: Inhibition  of pH]8 -OH-DPAT binding by ISmer GAGA in w hole  cells expressing 
hum an S-HTj^ receptors. Results are expressed as the mean ± SEM of at least 3 experiments run 
in triplicate. Conditions are as described in the Materials and Methods section.
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Figure 1 1 : Concentration-dependent inh ib ition  of [ H18-OH-DPAT by ISmer GAGA in
m em brane preparations o f the hum an S-HTia receptor. Results are expressed as the m ean ± SEM 
of at least 3 experiments run in triplicate. Conditions are as described in the M aterials and  
M ethods section.
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Figure 12: D isplacem ent o f specifically-bound [^H]8 -OH-DPAT from solub ilized  human 
receptors by  ISmer GAGA* Results are expressed as the mean ± SEM of at least 3 experiments 
run in triplicate. C onditions are as described in the Materials and Methods section.
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Figure 13: Inhibition of forskolin-stim ulated cAMP accumulation by 5-HT and ISmer GAGA. 
Peptide concentration was 124 (iM. Results are m eans ± SEM of 4 (forskolin), 5 (5-HT), 4 (5-HT + 
peptide), and 7 (peptide) experiments w ith n = 9. Values are expressed as percent of forskolin- 
stim uated cAM P, w hich w as 675.85 ± 67.14 fmol. Statistical significance w as defined w ith a 
repeated m easures ANO VA using Fisher PLSD (** = p < 0.001). Conditions are as described in 
the M aterials and Methods section.
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C. l lm e r  Peptide
The l lm e r  pep tide  is from a site d istinct from  the peptides of the ISm er 
fam ily, designed to m im ic the TM 3/i2 region of the h u m an  5-HT^^ receptor. 
The l lm e r  also gave a concen tra tion -dependen t d isp lacem ent of pH]8-OH- 
DPAT in w hole cells expressing the hum an  5-HT^^ receptor (figure 14) as w ell 
as m em brane (figure 15), and solubilized (figure 16) p reparations of th e  
receptor. Analysis revealed IC50 and  K. values in the low  m icrom olar range. 
Unlike the i3 loop peptides, there w as a m arked  difference in the potencies of 
the peptides betw een the various receptor p reparations. The w hole cell 
param eters w ere about threefold tim es tha t of the m em brane and eightfo ld  
tim es that of the solubilized receptor values (table 5). This m ay indicate th a t 
the l lm e r ,  unlike ISm er G A and GAGA peptides, has difficulties in crossing 
cellu lar m em branes.
Table 5: IC5 0  and K; Values for llm e r  Peptide. Values expressed in [oM.
Receptor Preparation IC 5 0 Ki
W hole cell 15.7 8.57
Membrane 6.71 3.66
Solub ilized 2 . 1 1 1.15
Average ± SEM 8.2 ± 4.89 4.5 ± 2.67
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Figure 14: Inhibition of agonist binding in  w hole cells expressing the human 5-HTia receptor by  
l lm e r  peptide. Results are expressed as the mean + SEM of at least 3 experiments run in 
triplicate. C onditions are as described in the Materials and Methods section.
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Figure 15: A bility  of l lm e r  to inhibit [ H]8 -OH-DPAT b ind ing in m embrane preparations of the 
hum an S-HT^a receptor. Results are expressed as the mean ± SEM of at least 3 experiments run 
in triplicate. Conditions are as described in the Materials and Methods section.
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Figure 16: D isplacem ent of [ H]8 -OH-DPAT in solubilized  human S-HT^a receptors by llm er .
Results are expressed as the m ean ± SEM of at least 3 experiments run in triplicate. Conditions 
are as described in the Materials and Methods section.
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Figure 17: Effects of llm e r  on forskolin-stim ulated cAMP accumulation in w h o le  cells
expressing the hum an S-HT^a receptor. Peptide concentration was 131 |iM. Results are means ± 
SEM of 4 experim ents run w ith  n = 4. Values are expressed as percent of forskolin-stim uated  
cAMPy w hich  w as 675.85 ± 67.14 fmol. Statistical significance was defined w ith  a repeated  
m easures A NO V A  using Fisher PLSD (** = p<0.001, * = p<0.01). Conditions are as described in 
the M aterials and Methods section.
33
W hen the l lm e r  w as tested in signal tran sd u c tio n  assays, the  pep tide  
d isp layed  m odest ability to inhib it fo rsko lin -stim ulated  cAMP form ation , bu t 
w as no t statistically significant (p<0.01) from  the controls. The p ep tid e  had  no 
effect on 5-HT m ediated  inhibition of cAMP (figure 17), being no t statistically 
d ifferen t from  5-HT alone (p<0.01).
D is c u s s io n
A . Summary of Results
Each of the synthetic pep tide probes of the h u m an  5-HT^^ receptors 
tested  p roduced  a concen tra tion -dependen t d isp lacem ent of the specifically- 
b o u n d  agonist pH ]8 -OH-DPAT from  the receptors. This w as observed in all 
p repara tions of the receptor, including the w hole cell p reparations, suggesting 
tha t each p ep tid e  w as able to gain at least m oderate intracellular access.
In the second m essenger assays only one of the peptides, ISm er GAGA, 
w as able to inh ib it fo rsko lin -stim ulated  cAMP greater than  50% of th e  
controls, w ith  the l lm e r  from  the i2  site exerting no significant effect o n  
cAM P production . Table 6  sum m arizes these results.
Table 6 : Summary of Results for the Peptide Probes of the Human S-HT^^ Receptor/ G Protein 
Interface.
P ep tide Apparent Kj (pM r % Inhibition of Forskolin
W hole Cell Membrane Solub ilized Stimulated cAMP ± SEM *
ISmer GA 31.6 37.6 28.4 31.4 ± S.O*
ISmer GAGA S8.4 61.6 49.6 S4.8 ± 6.2**
llm e r 8 . 6 3.7 1 . 2 20.9 ± 14.1
 ̂W hole cell, m em 3 rane, and solubilized indicate the preparation of the receptor in w hich the
Kj w as determ ined.
 ̂Expressed as percent of controls treated w ith 30 |iM  forskolin. Statistical significance from  
controls w as defined w ith a repeated m easures A NO VA  using Fisher PLSD (* = p < 0.01, ** = p 
< 0 .001).__________________________________________________________________________________________
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B. Inhibition of [^H]8-OH-DPAT Binding by the Peptide Probes
15mer GA w as observed to displace bound  agonist over a very n a rro w  
concentration  range, and  m axim al inhibition obtained w as w ith o u t exception 
less th an  100%. The degree of inh ib ition  w as h ighest in the so lub ilized
receptor p reparations w here 114 |iM  15mer GA resulted  in approxim ately  85%
inhibition  of [^H]8 -OH-DPAT binding, w hereas in the o ther p repara tions th is 
concen tra tion  produced  approxim ately 70% inhibition. C oncentrations of
15mer GA h igher than  114 |liM w ere no t investigated  due to solubility lim its
of the pep tide.
D ue to its lack of potency, com bined w ith  the narrow  concen tra tion - 
effect range observed, the 15mer GAGA proved  to be problem atic. T hese 
factors com bined to allow  only three concentrations to be investigated  in th e
agonist inh ib ition  studies. At the highest concentration  run , 124 |iiM, th e
pep tide  w as able to p roduce inh ib ition  only slightly greater than  50% in all
th ree p reparations of the receptor. C oncentrations greater than  124 |iM  w ere
no t investigated , again because of solubility lim its, w hile concentrations of
GAGA less than  10 jiM had no effect on specifically-bound agonist. T h is
suggests tha t the alterations to the GA pep tide in GAGA w ere effective in  
fu rther reducing  the ability of the pep tide  to uncouple the G p ro te in  from  th e  
receptor, as ev idenced by and IC50 values approxim ately  tw ice tha t for th e  
GA p ep tid e  in  each assay format.
36
The fact tha t bo th  ISm er GA and GAGA w ere slightly m ore active in  
w hole cell p reparations than  that of m em brane p reparations is surprising , as 
b o th  these peptides are highly charged and  displays generally hyd roph ilic  
characteristics. U pon closer exam ination , the overall secondary structu re  of 
the pep tide  m ay play a role in its access to the cytoplasm . There is ev idence 
th a t h igh ly  cationic peptides like m ellitin , a 27 am ino acid residue peptide 
from  bee venom , can gain in tracellu lar access (51). This pep tide assum es a n
a-helical like secondary structu re w ith  its h ighly  charged N -term inus, and
can bore holes th o rough  cellular m em branes-thus exerting one of bee 
venom ’s cytotoxic effects. The m ode of action m ay be sim ilar w ith  the altered 
ISm ers, as they have a h ighly  cationic C -term inus and can probably assum e
an a-helical like structure. This, com bined w ith  a m ore physiologically-intact
system  than  tha t of the receptors in the m em brane preparations, m ay h av e  
allow ed m ore efficient receptor or pep tide  coupling to the G protein.
The l lm e r  also displayed a concen tra tion -dependen t inh ib ition  of 
agonist b inding , bu t this effect w as observable over a m uch  larger 
concen tration  range than  w ith  the altered ISm er peptides. Perhaps m o re  
no tew o rth y  how ever, is tha t the l lm e r  achieved sim ilar levels of in h ib itio n  
of [^H]8 -OH-DPAT b inding  at approxim ately  tenfold less concentration  th a n  
ISm er GA. As expected, the l lm e r  w as m ost po ten t w ith  respect to agonist 
inh ib ition  in  solubilized receptors. H ow ever, un like the altered IS m er 
pep tides, the l lm e r  from  i2  w as not m ore active in the intact cells co n ta in in g  
the recep tor than  in m em brane p reparations. In fact, the ability of the l lm e r
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to displace specifically-bound [% ] 8 -OH-DP AT seem ed to be p ropo rtional to 
how  physiologically intact the system  w as. M axim al effect w as approxim ately  
55% inh ib ition  of b ind ing  in the w hole cell assays, w here 65% and 75% was 
observed  in m em brane and solubilized receptors respectively. F u rth e rm o re , 
the concentration of pep tide  needed to achieve a m axim al inh ib ition  of pH]8-
OH-DPAT b ind ing  in w hole cells, 210 pM , w as m ore than  twice tha t needed
in m em brane and  solubilized receptors.
There w as m ore than  a doubling  in Kj and values from  th e
solubilized to the m em brane preparations, and  a further doubling  again fro m  
m em brane to the w hole cell p reparations. This suggests tha t lip id  
m em branes pose a substantial barrier to the l lm e r  peptide, certainly m o re  
th an  the altered  15mers. This is som ew hat su rprising  as the l lm e r  displays a 
m ore hydrophobic character than  the 15mers. The l lm e r  carries ne t p o sitiv e  
charge of one, w hile the 15mers are h ighly  cationic peptides w ith  net charges 
in the 4-5 to 4-6 range.
It should  be m entioned at this po in t that interaction betw een G p ro te in  
and  all of the pep tide probes has no t been observed directly, and it is en tire ly  
possible tha t the peptides m ay be acting at a site distinct from  the proposed  
b ind ing  betw een the G pro tein  and  receptor. A nother possibility is tha t these  
pep tides are active at sites in add ition  to the proposed b ind ing  sites: due to
the experim enta l observations from  the increasingly m odified i3  site, th e  
sim ilarity  of the IC50 values for each pep tide regardless of receptor
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prepara tion , and the sm ooth  sigm oidal shape of the ag o n is t-in h ib itio n  
cu rves.
The l lm e r  potently  displaced bound  agonist in a concen tra tion - 
d ep en d en t m anner, p rov id ing  som e evidence tha t it can effectively com pete 
w ith  the receptor for G pro tein  binding. H ow ever, it displayed m u ltip h as ic  
concentration-effeet curves in the m em brane and solubilized receptors (see 
figures 15 and  16). This type of character in b ind ing  experim ents m ay indicate 
add itiona l site(s) of interaction, so it is possible tha t there are o th e r 
m echanism s th rough  w hich the l lm e r  is able to displace bo u n d  agonist, 
ra ther than  uncoupling  the G protein  only at the proposed  12 site.
C. Cyclic A M P  Assays
The fact that bo th  ISm er GA and GAGA w ere able to significantly  
inh ib it fo rskolin -stim ulated  cAMP lends sup p o rt to the idea tha t these 
pep tides are able to no t only bind to the G pro tein , b u t also can assum e a 
conform ation  sim ilar to the activated receptor. This w ould  then  activate th e  
G pro tein , and  in  our system  subsequently  inh ib it cAMP form ation. That a 
pep tide  could regulate G pro tein  function  is no t un h eard  of, as severa l 
am ph ipath ic , cationic peptides have been show n to in teract w ith  G p ro te in s  
(51). M astoparan, a am phipathic te tradecapeptide isolated from  w asp v e n o m , 
has been show n to regulate som e G pro teins, inc lud ing  Q , by s tim u la tin g  
GTPase activity (52). A lthough  there is som e d ispu te  over the exact
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m echanism , one possibility appears to be a direct in teraction  w ith  the carboxy
tail of (53). M astoparan  shares som e characteristics w ith  15mer GA and
GAGA: it is sim ilarly  sized and sim ilar in am ino acid com position, w ith
lysine residues near the term ini of the pep tide.
That ISm er GAGA w as m ore effective than  ISm er GA in in h ib itin g  
cAM P form ation is surprising. It is a possibility tha t the charged cationic and  
large hydrophobic side chains p resen t in the original sequence m otif -RFRI- 
favors coupling  to the G protein , b u t no t necessarily the full activation of Q . 
As the sequences deviate from  those tha t are found in the native receptor 
sequence, the loss of the side chains in tha t m otif w hich m akes the receptor 
progressively  less able to couple w ith  the G pro tein , could increase th e  
receptor's ability to activate the G protein . This could serve as a 
com pensato ry  m echanism  that has evolved betw een the G pro tein  and  
receptor to preserve an overall coupling constant.
Perhaps the loss of the bulky side chains from  -GARI- to -GAGA- 
allow s the pep tide to assum e a conform ation  of b ind ing  tha t is m o re  
conducive to G pro tein  activation. As G p ro te in  b ind ing  and G p ro te in  
activation  are tw o distinct processes (54), th is idea is plausible. D espite th e  
ISm er GA's apparen tly  m ore po ten t actions on b inding  to the G protein , as 
ev idenced by agonist inh ib ition , it m ay be tha t the steric h indrance  does n o t 
allow  the largely cationic tail of the pep tides to interact w ith  the ac tiv a tio n  
dom ains on the G p ro te in  in ISm er GA, b u t no t in  ISm er GAGA. T hese
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cationic residues have been im plicated in G p ro te in  activation in 7TM /G PCR 
system s (41, 54-55).
The l lm e r  from  i2 produced  a m odest decrease in  cAMP fo rm atio n , 
b u t it w as no t statistically significant w hen  com pared to the forskolin- 
s tim u la ted  controls. That the 12 peptide could no t inhib it cAMP fo rm a tio n  
raises the possibilities th a t this pep tide cannot m im ic the activated receptor 
conform ation , or tha t the 12 site does no t convey the agon ist-m ediated  
m essage to the G protein. This fits w ith in  the curren t m odel of TTM/GPCRs: 
a lthough  all cytoplasm ic loops are thought to p lay  a role in receptor-G  p ro te in  
coupling  and  activation, 13 is though t to be the m ain  site for co m m u n ic a tio n  
of receptor signaling to the G pro tein  as w ell as b ind ing  (56-57). This th e n  
positions the G p ro te in  w here fu rther conform ational changes allow  o th e r 
cytoplasm ic loops to in teract w ith  the G pro tein  including  12. It is the action  
of all the in tracellu lar contact sites coalescing on the G pro tein  tha t is th o u g h t 
to elicit full agonist activation of the G protein.
H ow ever, there is the possibility tha t the l lm e r  m ay not be reaching a 
h igh  en o u g h  in tracellu lar concentration. As show n in the b ind ing  data, th e  
l lm e r  at the m ax im um  concentration  exam ined w as able to displace on ly  
slightly  m ore th an  50% of bound  agonist in w hole cells expressing th e  
receptor. C om parison to its activity in the o ther p reparations suggests tha t it 
m ay  be tha t the lack of in tracellu lar access, not necessarily the pep tide  itself, 
th a t lim its the l lm e rs  efficacy in activating the G protein.
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D. Comparison of the i3 Loop Peptide Family
The bioactive pep tide know n as the 15mer from  the i3 region of the  
h u m a n  5-HT^^ receptor w as characterized in ou r lab in 1996 (40). B inding  
param eters are sum m arized  in table 7. It is this ISm er u p o n  w hich  th e  
altered  ISm ers GA and GAGA are based.
Table 7: ICjq and K; V alues for ISmer. Values expressed in pM. 
calculated from ICgo values in Hayataka, et aL (40)
Apparent K, values for 15mer
Receptor Preparation ICgo Ki
W hole cell 5.5 3.0
Membrane 3.0 1 . 6
Solu b ilized 0.5 0.3
W hen the actions of ISm er GA and 15mer GAGA are com pared  to th e  
original ISm er pep tide  (native sequence) from  N -term inus of the i3 loop, an  
in teresting  pattern  em erges. D esignating the b ind ing  param eters for ISm er as 
unity , w hole num ber ratios can be calculated and  com pared  for the ISm er GA 
and  GAGA peptides, presented in table 8 .
Table 8 : Ratios o f K; V alues for the Synthetic Probes from i3 Loop Family
P ep tide W hole N um ber Ratio
W hole cell Membrane S olu b ilized
15mer 1 1 1
15mer GA 1 1 23 104
15mer GAGA 19 38 182
G A /G A G A  ratio 0.54 0.61 0.57
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In the w hole cell p reparation , GA pep tide  displayed a ten-fold low er 
potency th an  the ISm er, w hile the GAGA alteration  w as just less than  tw o­
fold low er in potency than  ISm er GA. This trend  continues in bo th  
m em brane p reparations and solubilized receptors, w here the greatest 
d isparity  exists betw een the ISm er and the altered ISm ers, w here th e  
difference w as about 100- and 200-fold for ISm er GA and ISm er GAGA 
respectively. This difference could be due to ISm er having  difficulty gain ing  
in tracellu lar access, m uch the sam e as the l lm e r . A lthough  the ISm er is 
from  a different site than  the l lm e r ,  the values are m uch m ore sim ilar to 
the i2 peptide, being only approxim ately tw ice those obtained for the ISm er in  
the ir respective p reparations, and show  a sim ilar decreasing trend  as th e  
p rep ara tio n  deviates from  a physiologically-intact system  (see table S for 
l lm e r  b ind ing  param eters).
W hen the altered ISm er pep tides are com pared to the paren t ISm er in  
the ir effects on cAMP form ation , all significantly inh ib it cAMP fo rm atio n , 
w hen  com pared to the fo rskolin -stim ulated  controls. W hen the degree of 
cAMP inh ib ition  is ranked, the ISm er GAGA w as by far the m ost effective 
(S4.8%), follow ed by ISm er GA (31.4%), w ith  the least effective inh ib ito r being 
the ISm er (10%). The ISm er how ever, w as ru n  at a ten-fold low er 
concentration  than  its altered  siblings. There is an inverse re la tionsh ip  w ith  
these peptides; the better the pep tide uncouples the receptor from  the G 
pro tein , the less able the pep tide is able to activate the G protein. The reason  
for th is is no t clear, b u t as p rev iously  stated it could be that an ev o lu tio n a ry
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flexibility has developed  in G protein-receptor com m unication , w here a 
decrease in the ability of a G protein  to couple could be com pensated  for by an  
increase in  the receptor's ability to activate the G protein . A gain, less steric 
h in d ran ce  in  the coupling region could p rov ide m ore co n fo rm atio n a l 
freedom  w ith  respect to the activating region.
Recently, som e data  has been generated to address requirem ents for th e  
leng th  of the peptide needed for specificity in G pro tein -pep tide  in te rac tions. 
P re lim inary  experim ents using  a pep tide w ith  the sequence of the o rig inal 
15mer, truncated  to a 6 m er (sequence: ARFRIR), retains the -RFIR- m o tif  
w hich  w as altered  in 15mer GA and GAGA. A t the tim e of w riting , the 6 m er 
has been tested in w hole cells expressing the h u m an  5-HT^^ receptor and  
m em brane p reparations of the receptor, as w ell in  the cAMP assays. Like th e  
o ther m em bers of the 15mer family, it too d isplays a co n cen tra tio n -d ep en d en t 
effect in  displacing pH ]8 -OH-DPAT from receptors, as show n in figure 18.
H ow ever, not all the ISm er's activity w as retained, as it w as v ir tu a lly  
eq u ipo ten t to ISm er GAGA in w hole cells. This m ay be due to lim ite d  
in tracellu lar access, and  fu rther experim ents in solubilized receptors w ill be 
needed  to determ ine if lipid m em branes pose obstacles to the tru n ca ted  
IS m er.
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Figure 18: Inhibition of agonist binding in w hole  cells and membrane preparations expressing 
the human S-HTi^ receptor by truncated ISmer peptide (6 mer). Results are expressed as th e  
mean ± SEM of at least 3 experiments run in triplicate. Conditions are as described in th e  
M aterials and Methods section.
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Figure 19: Effects of 6 mer on forskolin-stim ulated cAMP accumulation in w h o le  cells  expressing 
the human 5-HTja receptor. 6 mer concentration w as 1 mM. Results are means ± SEM of 2 
experim ents run w ith n = 6 . Values are expressed as percent of forskolin-stim uated cAMP, 
w hich  was 2.59 ± 0.2 nmol. Statistical significance w as defined w ith  a repeated measures 
A N O V A  using Fisher PLSD = p<0.001, * = p<0.01). Conditions are as described in th e  
M aterials and Methods section. FSK = forskolin.
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W hen  exam ined in  the cAMP assays, the 6 m er pep tide at 1 m M  
concen tra tion  w as unable to significantly inh ib it cAMP accum ulation , w h e n  
com pared  to the forskolin-stim ulated controls, as show n in figure 19. A gain, 
it has no t been determ ined  if lipid m em branes pose obstacles to in trace llu la r 
access to the 6 m er, so there is a possibility tha t the peptide m ay n o t reach a 
h igh  en o u g h  in tracellu lar concentration to activate G ,̂ even if w ere able to do 
so.
The results from  the truncated  6 m er contribute to an em erging  p ic tu re  
of the struc tu ra l and  conform ational requ irem ents for a peptide-G  p ro te in  
coupling  a n d /o r  activation  at the i3 site. Further experim ents deta iling  
pep tide  in teraction  directly w ith  the G p ro te in  using th ree -d im en sio n a l 
nuclear m agnetic resonance spectroscopy (3 D-NMR) w ould  help  to 
u n d ers ta n d  m ore clearly the peptide-G  p ro tein  interactions. C ircu lar 
d ich ro ism  (CD) spectra, w hen  com bined w ith  m olecular m o d e llin g  
techniques could p roduce b ind ing  and coupling conform ations of th e  
peptides, allow ing fu rther u n d erstan d in g  of the structu ra l and  
confo rm ational requ irem ents involved in receptor-G  p ro te in  
com m unication . Expression of cloned G pro teins can p rov ide the necessary 
am o u n ts of m ateria l for these studies. O ther fu ture d irections in v o lv in g  
synthetic p ep tid e  probes, o ther than  stated above, are determ in ing  in a m o re  
d irect fashion the pep tides G pro tein  b ind ing  and activating properties.
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E. Conclusions
Based upon  the in form ation  presen ted  for this thesis, severa l 
conclusions can be draw n:
1. The synthetic peptide probes of the h u m an  5-HTj^ recep to r/G p ro te in  
interface stud ied  here w ere able to displace a specifically-bound agonist, pH]8- 
OH-DPAT, in a concen tra tion-dependen t m anner. This observation  is 
consisten t w ith  com petition  betw een the peptides and the receptor for 
b ind ing  site(s) on the G protein. This effectively uncouples the receptor fro m  
the G protein , shifting the receptor from  a h igh  to low affinity state for b o u n d  
agonist.
2. The tw o peptide probes from  i3 region investigated  significantly  
decreased cAMP form ation , w hen  com pared to the fo rsk o lin -s tim u la ted  
controls, suggesting tha t the i3 peptides m ay be able m im ic the activated  
receptor, thus activating G,. The pep tide  from  the in tracellu lar loop 2 reg ion , 
d id  n o t significantly decrease the form ation  of cAMP, w hen  com pared  to th e  
controls. These results suggest that the 12 pep tide m ay no t be able to activate 
the G pro tein , or tha t 13 m ay be involved  to a greater degree th an  12, w ith  
respect to G p ro tein  activation.
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3. W hen com paring  the activity of the altered i3 peptides to tha t of th e  
p a ren t pep tide probe, non-conservative  am ino acid substitu tions in a 
conserved -RFRI- m otif drastically reduced the ability of the pep tide to 
displace specifically-bound agonist, w hile the substitu tions im proved  th e  
pep tides ability to decrease cAMP form ation. These observations raise th e  
possibility tha t the -RFRI- m otif in i3 m ay be necessary for efficient receptor-G  
p ro te in  coupling, b u t is no t essential for receptor m ediated  G p ro te in  
activation in the hum an  S-HTj^ receptor.
A ppendix I: Structures of the Peptide Probes
A. Methods
T hree-d im ensional so lu tion  structures of the synthetic pep tide  probes 
w ere generated  using  Sybyl® m olecular m odelling  softw are (Tripos, Inc. St. 
Louis, MO) ru n n in g  on a Silicon G raphics Indigo 2® w orkstation. P rim ary  
sequences of the peptides w ere entered, and assigned form al charges at pH  7.4. 
D ielectric constan t w as 80.0. S tructures w ere then  energy-m inim ized th ro u g h  
at least 300 iterations.
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A ppendix II: Trim ethyltin/Protein Kinase C®
^This research was presented as a poster entitled "Differential A ctivation of 
C6  Glioma Protein Kinase C Isozym es by a Phorbol Ester and Trim ethyltin" a t  
the W estern Pharmacology Society’s 40th annual meeting in Banff, A lberta , 
Canada and w as published in the Society's proceedings that year (1997) as an 
abstract:
Ortiz, T.C., Parker, K.K., Eyer, C.L. D ifferential activation of C6  gliom a  
protein kinase C isozym es by a phorbol ester and tr im eth y ltin  Proceedings o f  
the W estern Pharmacology Society, (1997)._____________________________________
A , Background
The research presen ted  in this appendix  w as com pleted w ith in  m y 
initial year a t The U niversity  of M ontana and  w as a laboratory ro tation for Dr. 
C harles Eyer over the span  of June 1996 to Decem ber 1996. The goals of th is  
project are to contribute in fo rm ation  to his ongoing research into th e  
biochem ical m echanism s of trim ethyltin  (TMT) neurotoxicity.
B. Introduction
The p o ten t n eu ro tox in  trim ethy ltin  (TMT) causes a delayed, 
irreversib le  dam age characterized by gliosis and  neu ro n al cell death , and  is 
h igh ly  specific to the hippocam pus, especially in  the pyram idal cells (58). T he 
biochem ical m echan ism s by w hich  this dam age occurs is no t w ell 
u n d ersto o d , therefore TMT’s role(s) in  the n eu ro n a l cell d ea th  is as of yet 
eludicated . D ue to the delayed na tu re  of its dam age, m etabotropic processes 
have  been  im plicated in the pathogenesis of TMT.
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Protein  Kinase C (PKC), an enzym e involved in  such cellular processes 
as transcrip tion , grow th, d ifferentiation , and  regu la tion  of o ther signaling  
pathw ays, has been im plicated in the dam age caused by TMT (59). Excessive 
or susta ined  activation of PKC has been im plicated in several 
neurodegenerative  processes, such as excitotoxic or ischemic dam age, as w ell 
as TMT toxicity. This has been p rev iously  reported  in  a cell line of n e u ro n a l 
orig in , the PC 12 pheochrom acytom a (60). T reatm ent w ith  TMT, caused a 
translocation  of PKC from  the cytosol to the m em brane, w hich correlated to 
cellular death  as m easured  by lactate dehydrogenase (LDH) release. This was 
p reven ted  in this m odel by trea tm ent w ith  a PKC inhibitor, or previous dow n 
regu la tion  of PKC w ith  phorbol 12-m yristrate 13-acetate (PMA), a PKC 
activator.
PKCs are a fam ily a serine / th reon ine kinases that are abundan t in a 
varie ty  of tissues, including  the CNS (61). Existing in at least 12 d ifferent 
isoform s, PKCs use the phosphatidy linosito l (PI) signal transduction  pathw ay 
and upon  activation, the enzym e translocates from  the cytosol to the  
m em brane (62-63). PKC isozym es are classified as either conventional (cPKC), 
new  (nPKC), or atypical (aPKC) according to their various requ irem ents for 
ac tivation  (64). A sum m ary  of PKC classification and requ irem ents for 
activation is p resented  in table lA .
This study  therefore, w as designed to exam ine the effects of TM T 
trea tm en t on specific PKC isozym e classes in an im m ortalized  glial cell line. 
M any know n isozym es of PKC have been reported  in a C6  gliom a cell lin e
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(65), thereby p rov id ing  a good m odel of TMT’s effects on PKC subclasses. 
U ltim ately , this inform ation will be used to establish  the roles of glial cells in  
TMT toxicity.
Table l(A II): PKC Isoform s. Adapted from Nishizuka, 1992 (64).
PKC Subclass Species A ctivators Phorbol Ester 
S en sitiv ity
cPKC a ,  PP, piP, Y PS, C a+\ DAG, FFA, 
LPC
yes
nPKC Ô ,  E ,  T[,  0, M - PS, DAG, FFA, 
C holesterol sulfate
(5)
yes
aPKC I, PS, FFA, PIP3 , Cer no
Cer = ceram ide, DAG = diacylglycerol, FFA = cis unsaturated fatty acids, LPC = 
lysop h osp h atid ty lcho lin e, PIP3 = phosphatidylinositol(fns)phosphate, PS = 
p h o sp h a tid y lser in e .
* The p isoform  has tw o identified splice variants.____________________________
C. Methods
(1) Cell cu lture and tre a tm e n t: Rat C6  gliom a cells w ere cu ltu red  in 70 
cm^ flasks using  H am 's F-12 m edia p lus 10% fetal calf serum  (PCS). C u ltu res 
w ere m ain ta ined  at 37°C and  5% COj. U pon confluency (7-10 days) m edia w as 
su bstitu ted  w ith  either Krebs-Ringer buffer (KRB); (125 m M  N aCl, 5 m M  KCl, 
25 m M  HEPES, 6  m M  glucose, 5 m M  NaHCO^, 1.2 mM  K^HPO^, 1 m M  C a C y  
or F -1 2 /10% FCS contain ing  appropria te  concentrations of either TMT or 
PM A. KRB treatm ents w ere used for 1 h o u r or less, w hile the F-12/10%  FCS 
w as substitu ted  for the 24 h o u r treatm ents. T reatm ents w ere stopped  by
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asp ira ting  m edia and w ashing  three tim es w ith  ice-cold KRB. Cells w ere 
collected by scraping from  the flask into 10 mL of ice-cold KRB and  by 
cen trifugation  at 4000 rpm  for 10 m inutes, decanting  the supernatan t.
(2) P reparation  of cellular extracts: Collected cells w ere resuspended  in  
lysis buffer (20 m M  Tris-HCl, 2 m M  EDTA, 5 m M  EGTA, 2 m M  DTT, 1 m M  
PMSF, 1 m g /m L  bacitracin, 10 |ig /m L  each of leupep tin  and aprotin in) and
hom ogen ized  on glass. Cytosolic and m em brane fractions w ere obtained by 
cen trifugation  40000 X g for 40 m in. at 4°C. Cytosolic (supernatant) fraction 
w as rem oved  and  the pellet (m em brane fraction) w as resuspended  in lysis
buffer p lus 1% Triton X-100. From each sam ple, 10 |iL aliquots w ere rem o v ed
to d eterm ine  p ro te in  concentration (45), w hile the rem ainder w as stored at - 
80°C un til analysis.
(3) Sam ple p repara tion  and W estern  b lo ttin g : Sam ples w ere analyzed 
based  u p o n  the m ethods described by Pavlakovic (60) and Schneppheim  (6 6 ).
Sam ples (20 |ig total pro tein) w ere m ixed w ith  an  equal vo lum e of 2X
solubiliz ing  buffer (50 m M  Tris-HCl, 2% SDS, 4% glycerol). They w ere th e n  
p laced  in a boiling w ater bath  for 90 seconds and fu rther sonicated 10 seconds 
at 10% cycle. Separation w as on 10% Laem m li polyacrylam ide gels u n d e r  
reducing  conditions and the pro teins transferred  to PVDF m em branes. Blots 
w ere then  im m ediately  placed into a blocking buffer (5% non-fat m ilk in Tris- 
buffered saline p lus 0.1% Tween-20 (TTBS)) for 1 hour. A fter blocking, th e
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m em branes w ere incubated for 1 h o u r in so lu tions of m onoclonal PKC 
antibodies (T ransduction Laboratories, Lexington, KY) directed at specific 
isoform s (1:1000 d ilu tion  in blocking buffer). M em branes w ere w ashed in  
TTBS, then  subsequent incubation  in an ti-m ouse IgG conjugated to 
h o rserad ish  peroxidase (HRP) (1:1000 d ilu tion  in blocking buffer) for 1 h o u r. 
Blots w ere v isualized  w ith  enhanced chem ilum inesence (ECL) and recorded 
on X-ray film.
D. Results
The presence of the a , p, y, Ô, e, 0, Ç, 1, and  |li isozym es w as established
in o u r C6  cell line by b lo tting  cellular extracts w ith  m onoclonal antibodies. 
These isozym es of PKC w ere then  evaluated  on their responses to PMA and  
TMT exposure. Some results from  these experim ents are presented  in figure 
lA . T ranslocation to the cell m em brane by cPKC and nPKC isoform s occurred 
w ith  the application  of PMA. Predictably, the aPKC isozym es w ere n o t
translocated  by this treatm ent. TMT exposure for up  to 1 h o u r did n o t 
translocate any of the PKC isoforms.
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Figure 1 (All): R esponse to of PKC to PMA and TMT at 1  hour. Top: D ifferential translocation  
betw een PKC a  (MW=82 kDa, upper arrow) and PKC (MW=72 kOa, lower arrow), a  can be 
seen to translocate from cytosolic to membrane fractions in the presence of PMA, but not the Ç 
isoform (lanes 3 and 4). N o translocation of either isoform is observed w ith 10 |iM  or 50 |iM TMT 
(lanes 5-8). Bottom: Shows PKC Ô under the same conditions. A gain, no translocation is  
observed in response to TMT. Lanes 1  and 2: untreated controls; lanes 3 and 4: 100 nM PMA; 
lanes 5 and 6 : 10 |oM TMT; lanes 7 and 8 : 50 |iM TMT.
PKCs a , Ô, Ç w ere also evaluated after 24 hou rs of trea tm en t w ith  PM A
and TMT. PKCs a  and ô had  dow n-regulated w ith  the PMA treatm ent, w h ile
no translocation  w as detected w ith  TMT trea tm en t on any isoform . T his 
leads to the conclusion that TMT is not able to translocate any isoform  of PKC 
in a glial cell m odel, and lends to the possibility that TM T-m ediated PKC 
activa tion  in the n eu ronal cell line is no t a direct effect, b u t is due  to an  
ind irect pathw ay.
A ppendix III: Natural Product Screening
A. Background
This appendix  presen ts data from  experim ents runn ing  in parallel w ith  
m y  thesis research in Dr. Keith Parker’s laboratory from  January  1997 to th e  
p resen t, and  involves screening n a tu ra l p roducts from  several d ifferen t 
sources for activity at cloned ra t receptors, stably expressed in N IH  3T3
fibroblasts (a gift from  Dr. D avid Julius, UCSF).
A m ong the n a tu ra l p roducts being investigated are P eruv ian  and  
E cuadorian  ethnobotanicals reported  to be used  in m igraine prophylaxis, 
obtained  by Dr. E than B. Russo of the W estern  M ontana Clinic, and crude 
v enom  from  several species of m arine cone snails {Conus sp. ), k ind ly  
supp lied  by Dr. D oug Steele, of the U niversity of U tah. Initially, the w ork  was 
p rim arily  done w ith  the ethnobotanicals, data from  these experim ents are 
p resen ted  in figure 2A.
As m ore Conus venom  sam ples becam e available from  o u r  
collaborators how ever, the focus of the project shifted in that direction, as did 
m y invo lvem en t. Thus the w ork  p resen ted  in this appendix  w ill be 
p rim arily  th a t of the various Conus venom  experim ents.
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Figure l(A III): A ctiv ity  o i ethnobotanical extracts of the genus G esneriad  in membrane
preparations of the rat S-HTja receptor. Plants are preserved and extracted in 70% eth an ol, 
diluted 1:10 in binding buffer, giving a final dilution of 1:100 of the crude extract in th e  
com petitive binding assay. V alues are of one experiment run in triplicate. Conditions are as 
described in the Methods section of this appendix.
B. Introduction
The predato ry  m arine snails of the genus C onus, m ore co m m o n ly  
k now n  as cone snails, u tilize a toxic venom  contain ing  an array of sm all 
peptides, term ed conotoxins, to im m obilize and capture their prey. T hese 
peptides are usually  10-30 am ino acids in length  and confo rm ationally  
constrained  either by m u ltip le  d isu lfide bonding , or hav ing  a stable tertiary
structu re  consisting of y-carboxyglutam ate helices (67). Each species has a
characteristic venom  com position  of conotoxins, w ith  a d istinct 
pharm acological profile (67). Peptides tha t have been isolated from  the crude
62
v en o m  in teract very  specifically at a num ber of biological targets. Sites of 
biological activity that have been thus identified are sum m arized  in table 2A.
C ertain  pep tides from  these classes can d istinguish  betw een subtypes of 
ion  channels (6 8 ), as w ell as d ifferential b ind ing  sites on the n ico tin ic  
acetylcholine receptors (69). C om bined w ith  this k ind  of specificity are 
generally  h igh  affinities, w ith  m ost K^'s in the low  m ic ro m o la r /h ig h  
n ano m o lar range (70). D ue to the com bination of these characteristics, these 
pep tides have been the subject of m uch investigation  for b o th  
pharm acological research tools, and as possible therapeutic agents.
Table l(A III): C lasses of Conotoxiiis and their Identified  Receptor Targets. Adapted from
O livera, et al. 1991 (67).
Conotoxin Class Receptor Target
a-C onotoxin N icotinic acetylcholine receptors
|i-Conotoxin V oltage-gated Na^ channels
co-Conotoxin V oltage-gated Ca^  ̂ channels
Conopressins Vasopressin receptors
Conantokins N -m ethyl-D -aspartate receptors
For m ost conotoxins, the specific sites of in teraction  have yet to be 
dete rm in ed  (67). To th is end, the goals of th is project are to first identify  
species of snails w hose venom  is active at sero ton in  2A receptors (S-HT^y^) by 
screening of crude venom  extracts. Secondly, the screening of successive h ig h  
perfo rm ance liquid  chrom atography (HPLC)-purified v enom  extracts fro m
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species tha t display activity are analyzed to determ ine  the receptor
active com ponent(s) of the venom .
C. Methods
The m ethods used in the com petitive b ind ing  assays are the sam e as 
sta ted  for m em brane p reparations in of receptor for agonist inh ib ition  assays 
in the body  of the thesis (see pages 22-24) w ith  the follow ing m odifications:
(1) Cell cu ltu re : N IH  3T3 cells expressing the ra t S-HTg^ receptor (gift
from  Dr. D avid Julius, UCSF) are cultured  in DMEM fortified w ith  200 pg /m L
Geneticin® or G 418 sulfate and 10% CS, instead of the fortified H am 's F-12 
m edia used  for the CH O  cultures.
(2) C om petitive b ind ing  assays: To obtain  m em brane p reparations of 
the ra t 5 -HT 2̂  receptor, no m odifications are needed  from  the m em b ran e  
p reparations of the h u m an  5-HT^^ receptor. C onditions for the b ind ing  assays 
are also identical, how ever non-specific b ind ing  is determ ined  in the presence 
of 10 pM  m ianserin , and  the conotoxins com pete for the specific b ind ing  sites 
w ith  0.25 nM  pH ]ketanserin  (specific activity of 250 C i/m m ol).
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D. Results
The first and only species from  the initial screen to be subject to fu rth e r 
s tudy  is the venom  from  Conus striatus (figure 3A). Despite its average 
ability to displace pH ]ketanserin  in the initial screen, it w as currently  being 
fractionated by Dr. Steele, thus m aking  sam ples readily available. The en tire  
ch ro m atag rap h  (data no t show n) from  a crude HPLC fractionation produced 
several fractions tha t w ere pooled to be screened for activity. Figure 4A show s 
resu lts from  these experim ents. A lm ost all of the activity in these sam ples 
w as contained  w ith in  pool seven (approxim ately  50% displacem ent).
Subsequently , as pooled fraction seven w as further fractionated, several 
peaks w ere identified and subject to fu rther scrutiny. The results from  these 
experim ents are p resen ted  in figure 5A. A gain, m ost of the original activity 
w as contained  w ith in  a single fraction, in this case num ber th irty -sev en  
d isp lay ing  greater than  50% displacem ent of specifically-bound pH jketanserin . 
This being the case, fraction th irty -seven  has been subjected to fu rther HPLC 
purification, and  again screened for activity at the rat 5 -HT 2̂  receptor.
W hen fu rther purifications becom e available, hopefully  the 5-HTg^ 
receptor active conotoxin(s) can be soon be elucidated. It is possible then, th a t 
a heretofore un iden tified  group of biological targets, receptors of the 5-HT 
fam ily, w ill have been identified  as a site of action for conotoxins. T he 
im plications are tha t of an  entirely  new  class of conotoxins (see table 2A).
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Figure 2(AIII): A ctiv ity  of crude venom extracts from various species of Conus in membrane 
preparations of the rat S-HTza receptor. Extracts are at a final dilution of 1:100, Values are of 
one experim ent run in triplicate. Conditions are as described in the M ethods  section of th is  
appendix. Tex = textile, fig = figulinus, alb = albidicus, mag = magus, bet = betulinus, rad = 
radius, str = striatus, geo = geographus, mar = marmoremus.
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Figure 3(AIII): A ctivity o f pooled  HPLC fractions from C. s tr ia tu s  venom extracts in membrane 
preparations of the rat S-HTja receptor. Venom extract concentration w as 0.5 mg per assay . 
Results shown for pools 1-4 are of one experiment run in triplicate, 5-8 are the results of three  
independent experiments. Conditions are as described in the Methods section of this appendix.
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Figure 4(AIII): A ctiv ity  of HPLC fractions from C. str ia tu s  venom extracts in membrane
preparations of the rat S-HTg^ receptor. Fractions were diluted in binding buffer to yield  a 
final concentration of -0 .5  mg per assay. Results shown are of at least 2 experiments run in 
triplicate ± SEM, C onditions are as described in the M ethods section of this appendix.
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